KR20070067719A - 백신용 면역조절제 - Google Patents

백신용 면역조절제 Download PDF

Info

Publication number
KR20070067719A
KR20070067719A KR1020077011045A KR20077011045A KR20070067719A KR 20070067719 A KR20070067719 A KR 20070067719A KR 1020077011045 A KR1020077011045 A KR 1020077011045A KR 20077011045 A KR20077011045 A KR 20077011045A KR 20070067719 A KR20070067719 A KR 20070067719A
Authority
KR
South Korea
Prior art keywords
infectious
etxb
ctxb
agent
infectious agent
Prior art date
Application number
KR1020077011045A
Other languages
English (en)
Korean (ko)
Inventor
티모시 레이몬드 허스트
네일 앤드류 윌리엄스
Original Assignee
유니버시티 오브 브리스톨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9809958.3A external-priority patent/GB9809958D0/en
Priority claimed from GBGB9812316.9A external-priority patent/GB9812316D0/en
Application filed by 유니버시티 오브 브리스톨 filed Critical 유니버시티 오브 브리스톨
Publication of KR20070067719A publication Critical patent/KR20070067719A/ko

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • AIDS & HIV (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020077011045A 1998-05-08 1999-05-10 백신용 면역조절제 KR20070067719A (ko)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GBGB9809958.3A GB9809958D0 (en) 1998-05-08 1998-05-08 Vaccine
GB9809958.3 1998-05-08
GB9811954.8 1998-06-03
GBGB9811954.8A GB9811954D0 (en) 1998-05-08 1998-06-03 Vaccine
GB9812316.9 1998-06-08
GBGB9812316.9A GB9812316D0 (en) 1998-06-08 1998-06-08 Cancer vaccines

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020007012486A Division KR20010043441A (ko) 1998-05-08 1999-05-10 백신용 면역조절제

Publications (1)

Publication Number Publication Date
KR20070067719A true KR20070067719A (ko) 2007-06-28

Family

ID=27269307

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020077011045A KR20070067719A (ko) 1998-05-08 1999-05-10 백신용 면역조절제

Country Status (18)

Country Link
EP (1) EP1075274A2 (ru)
JP (1) JP4666761B2 (ru)
KR (1) KR20070067719A (ru)
CN (1) CN100335130C (ru)
AU (1) AU3939499A (ru)
BR (1) BR9910305A (ru)
CA (1) CA2331832A1 (ru)
CZ (1) CZ302333B6 (ru)
EA (1) EA004794B1 (ru)
GB (1) GB2353472A (ru)
HU (1) HUP0104842A3 (ru)
IL (1) IL139467A (ru)
IS (1) IS5694A (ru)
MX (1) MXPA00010934A (ru)
NO (1) NO20005599L (ru)
NZ (1) NZ507911A (ru)
PL (1) PL344519A1 (ru)
WO (1) WO1999058145A2 (ru)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9513371D0 (en) 1995-06-30 1995-09-06 Biocine Spa Immunogenic detoxified mutant toxins
GB9326174D0 (en) 1993-12-22 1994-02-23 Biocine Sclavo Mucosal adjuvant
US20010036917A1 (en) 1995-07-05 2001-11-01 Williams Neil Andrew Therapeutic agents
GB9622660D0 (en) 1996-10-31 1997-01-08 Biocine Spa Immunogenic detoxified mutant toxin
US6818222B1 (en) 1997-03-21 2004-11-16 Chiron Corporation Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants
US7914791B1 (en) 1998-05-08 2011-03-29 Trident Pharmaceuticals, Inc. Vaccine
US7115730B1 (en) 1999-04-27 2006-10-03 Chiron Srl Immunogenic detoxified mutant E. coli LT-A-toxin
GB0030067D0 (en) * 2000-12-11 2001-01-24 Univ Bristol Therapeutic agent
GB0115382D0 (en) * 2001-06-22 2001-08-15 Univ Bristol Mutant
CN111100824B (zh) * 2020-01-21 2021-11-05 暨南大学 一株芽孢杆菌及其在养殖水体中脱氮除硫的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0372928A3 (en) * 1988-12-07 1990-06-27 University Of Leicester Heat-labile toxin b subunit fusion proteins
US5241053A (en) * 1990-09-05 1993-08-31 Takeda Chemical Industries, Ltd. Fused proteins comprising glycoprotein gD of HSV-1 and LTB
GB9513733D0 (en) * 1995-07-05 1995-09-06 Univ Bristol Therapeutic agents
EP0919243A1 (en) * 1997-11-25 1999-06-02 Duphar International Research B.V Vaccine containing B subunits of heat-labile enterotoxin (LTB) of Escherichia coli as an adjuvant
AU2232399A (en) * 1998-01-16 1999-08-02 Maxim Pharmaceuticals, Inc. Recombinant ctb-based vaccines

Also Published As

Publication number Publication date
IL139467A0 (en) 2001-11-25
GB0027072D0 (en) 2000-12-20
CZ302333B6 (cs) 2011-03-16
WO1999058145A2 (en) 1999-11-18
CN100335130C (zh) 2007-09-05
JP4666761B2 (ja) 2011-04-06
IL139467A (en) 2011-11-30
BR9910305A (pt) 2001-01-09
CA2331832A1 (en) 1999-11-18
JP2002514607A (ja) 2002-05-21
MXPA00010934A (es) 2003-07-14
NO20005599L (no) 2001-01-08
EA200001134A1 (ru) 2001-08-27
NO20005599D0 (no) 2000-11-06
NZ507911A (en) 2004-04-30
EA004794B1 (ru) 2004-08-26
HUP0104842A2 (hu) 2002-04-29
WO1999058145A3 (en) 2000-02-03
CN1308546A (zh) 2001-08-15
IS5694A (is) 2000-10-31
AU3939499A (en) 1999-11-29
PL344519A1 (en) 2001-11-05
GB2353472A (en) 2001-02-28
CZ20004147A3 (en) 2001-05-16
EP1075274A2 (en) 2001-02-14
HUP0104842A3 (en) 2002-12-28

Similar Documents

Publication Publication Date Title
Hunter et al. Production of gamma interferon by natural killer cells from Toxoplasma gondii-infected SCID mice: regulation by interleukin-10, interleukin-12, and tumor necrosis factor alpha
Sin et al. In vivo modulation of vaccine-induced immune responses toward a Th1 phenotype increases potency and vaccine effectiveness in a herpes simplex virus type 2 mouse model
CA2169635C (en) Method, compositions and devices for administration of naked polynucleotides which encode biologically active peptides
Eo et al. Immunopotentiation of DNA vaccine against herpes simplex virus via co-delivery of plasmid DNA expressing CCR7 ligands
Richards et al. Protective mucosal immunity to ocular herpes simplex virus type 1 infection in mice by using Escherichia coli heat-labile enterotoxin B subunit as an adjuvant
Gierynska et al. Induction of CD8 T-cell-specific systemic and mucosal immunity against herpes simplex virus with CpG-peptide complexes
Jayaraman et al. Exacerbation of murine herpes simplex virus-mediated stromal keratitis by Th2 type T cells.
Toka et al. Codelivery of CCR7 ligands as molecular adjuvants enhances the protective immune response against herpes simplex virus type 1
Cong et al. Multi-epitope DNA vaccine linked to the A2/B subunit of cholera toxin protect mice against Toxoplasma gondii
JP2009161568A (ja) アレルギー性状態または過敏症状態を処置するための薬剤
KR20070067719A (ko) 백신용 면역조절제
Fló et al. Superiority of intramuscular route and full length glycoprotein D for DNA vaccination against herpes simplex 2. Enhancement of protection by the co-delivery of the GM-CSF gene
Chiarantini et al. Red blood cells as delivery system for recombinant HSV-1 glycoprotein B: immunogenicity and protection in mice
US20030108514A1 (en) Chemokines as adjuvants
Mackenzie-Dyck et al. The synthetic peptides bovine enteric β-defensin (EBD), bovine neutrophil β-defensin (BNBD) 9 and BNBD 3 are chemotactic for immature bovine dendritic cells
US7914791B1 (en) Vaccine
AU2003261492B2 (en) Vaccine
US20040067240A1 (en) Therapeutic agent comprising a b-subunit of a protein toxin
AU2002222153A1 (en) Therapeutic agent comprising a B-subunit of a protein toxin
AU2006249261A1 (en) Vaccine
Maeyama et al. Cytokine responses to recombinant cholera toxin B subunit produced by Bacillus brevis as a mucosal adjuvant
Zhang et al. Enhanced efficacy of CTLA‐4 fusion anti‐caries DNA vaccines in gnotobiotic hamsters 1
US20040037844A1 (en) Vaccine
Lethal The Trypanosoma cruzi Tc52-Released
Sohrabi et al. Pseudomonas aeruginosa flagellin as an adjuvant: The superiority of the conjugated form of flagellin versus the mixed one to an HIV-1 vaccine candidate in the induction of immune responses

Legal Events

Date Code Title Description
A107 Divisional application of patent
A201 Request for examination
E902 Notification of reason for refusal
E601 Decision to refuse application